Key result
High anticholinergic drug burden linked to ~78% higher all-cause mortality in older adults.
Why the study?
The study aimed to evaluate the association of anticholinergic burden and chronic polypharmacy with functional decline and all-cause mortality, and to determine the difference between them in Korean older people.
Does anticholinergic burden or chronic polypharmacy increase functional decline and all-cause mortality in older people?
Cohort (n=42,132)
Does anticholinergic burden or chronic polypharmacy increase functional decline and all-cause mortality in older people?
Effect estimate: HR 1.78 (95% CI 1.35-2.35)
Absolute Event Rate: 18.4% vs 9.6%
p-value: p=< 0.001
Anticholinergic drug burden is more strongly associated with functional decline than chronic polypharmacy, and both are significant independent risk factors for all-cause mortality in older adults.
High anticholinergic burden was associated with higher mortality in older adults; leaves open whether deprescribing improves outcomes.
BACKGROUND: We aimed to evaluate the association of anticholinergic burden and chronic polypharmacy with the incidence of functional decline and all-cause mortality, and to determine the difference between anticholinergic burden and chronic polypharmacy among Korean older people. METHODS: This nationwide cohort study included 42,132 older people aged ≥ 65 years who underwent Korean National Health Insurance Service health examinations from 2007 to 2008. Odds ratios (ORs) and 95% confidence intervals (CIs) for abnormal Timed Up and Go (TUG) test results were assessed using multivariate logistic regression analyses. Hazard ratios (HRs) and 95% CIs for all-cause mortality until the end of 2015 were estimated using multivariable Cox proportional hazards regression analysis. RESULTS: Of the participants, 37.19% had abnormal TUG test results, and 7.66% of those died during the 5.7-year mean follow-up. The abnormal TUG test results OR increased by 27% among individuals with Korean Anticholinergic Burden Scale (KABS) scores ≥ 3 (OR 1.27, 95% CI 1.02-1.58) compared to those with KABS scores of 0. The HRs for all-cause mortality increased for individuals with higher KABS scores (P for trend < 0.001) or chronic polypharmacy (P for trend < 0.001) compared to those for individuals without these conditions. The combination of a higher KABS or chronic polypharmacy and abnormal TUG test results increased the risk of all-cause mortality (All P for trend < 0.001). CONCLUSION: Anticholinergic drug burden shows a better association with functional decline than chronic polypharmacy, and the use of medications and functional decline may be important risk factors for all-cause mortality among older people.
No takes yet. Share an insight, caveat, or question.
Huh et al. (2024) conducted a cohort in Older adults at risk of functional decline and mortality (n=42,132). High anticholinergic burden (KABS score ≥ 3) vs. No anticholinergic burden (KABS score 0) was evaluated on All-cause mortality (HR 1.78, 95% CI 1.35-2.35, p=< 0.001). A high anticholinergic drug burden (KABS score ≥ 3) significantly increased the risk of all-cause mortality by 78% (HR 1.78) compared to no anticholinergic burden in Korean older adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: